Introduction
Prognosis of patients with refractory metastatic sarcomas is poor with response rates in the range of 10-30%. Approaches to dose intensification by high-dose chemotherapy (HDCT) with the use of PBSC transplantation have raised objective response rates to 20-65%, but failed to show any OS benefit. [1] [2] [3] However, in some phase I trials using HDCT, long-term survivors have been reported. 4 In patients with germ cell cancer (GCC) resistant to platinum-based chemotherapy, the therapeutic outcome is also very poor. The role of HDCT in this setting is still a matter of debate, but it might be beneficial as salvage therapy, as suggested by the European Germ Cell Cancer Consensus Group. 5, 6 Bevacizumab (Avastin, Roche AG) is a humanized antibody that binds to vascular endothelial growth factor (VEGF) that is made by tumor cells to promote vessel formation. 7 By various mechanisms of action, bevacizumab augments the activity of conventional chemotherapy in epithelial neoplasms such as colorectal, breast and lung cancer. 8 However, the majority of soft tissue sarcomas have been found to express VEGF. 9 and VEGF receptor inhibitors have shown antitumor activity in this type of tumor. 10, 11 Significantly increased VEGF expression has also been reported in metastatic GCC. 12 These tumors, therefore, represent a rational target in which to perform therapeutic testing of bevacizumab in combination with HDCT. It was hypothesized that the marginal benefit of HDCT might be improved by the addition of bevacizumab because tumor vascular function and tumor uptake of anticancer drugs improve with VEGF-blocking therapy. 13 
Patients and methods

Patient eligibility
Eligible patients had histologically confirmed metastatic sarcoma or GCC. Patients were required to be refractory to standard chemotherapy but not to have had prior HDCT. Other inclusion criteria were an ECOG performance status of at least two and adequate hematologic, hepatic and renal functions. Patients with newly diagnosed venous thrombosis or other condition requiring anticoagulation, clinically significant cardiovascular disease or surgery within 21 days were excluded. Presence of cerebral metastases was not an exclusion criterion. Written informed consent was obtained. The study was conducted in accordance with the Helsinki declaration and guidelines on good clinical practice.
Treatment
Patients were treated first with SD-ICE with or without bevacizumab (the first three patients without bevacizumab) 7.5-10 mg/kg (ifosfamide 1500 mg/m 2 d1-3, carboplatin 150 mg/m 2 d1-3, etoposide 150 mg/m 2 d1-3) including separation of stem cells. If 410 CD34 þ cells/mL were found in peripheral blood, separation of stem cells was performed to harvest 10 Â 10 6 CD34 þ cells/kg body weight (2 Â 10 6 CD34 þ cells/kg body weight for each HD-ICE cycle and one sac 2 Â 10 6 CD34 þ cells/kg body weight kept in reserve). If insufficient amounts of cells were harvested, a second cycle of SD-ICE with separation of stem cells was performed. Patients then received HD-ICE (ifosfamide 3000 mg/m 2 d1-3, carboplatin 300 mg/m 2 d1-3, etoposide 300 mg/m 2 d1-3) plus bevacizumab (7.5-10 mg/kg) on day 1 (Bevacizumab was started with a dose of 7.5 mg/kg for the first 6 patients. When no toxicity typically ascribed to bevacizumab occurred, the dose was escalated to 10 mg/kg). Patients received PBSC transfusion on day 5 and granulocytecolony stimulating factor (pegfilgrastim or filgrastim) until recovery of neutrophils. Therapy was repeated every 3 weeks for up to 4 cycles of HDCT. Cytotoxic drug administration was delayed by 1 week if there was not full hematological recovery (WBC43 Â 10 9 /L, platelets 4100 Â 10 9 /L). In the event of an impaired creatinine clearance, the dose of cytotoxic drug was reduced by at least 25%. Patients remained on study until disease progression or unacceptable toxicity occurred.
Baseline and treatment assessment
Baseline evaluation included assessment of ECOG performance status, standard hematology, chemistry, liver function tests, urinanalysis, creatinine clearance including assessment of proteinuria, physical examination and echocardiogram. An ECG was performed before each treatment cycle and an echocardiogram was performed every 2 cycles. Each patient underwent radiological imaging (including CT, MRI or X-ray) at baseline for tumor measurement, to be repeated every 3 weeks before starting the next chemotherapy cycle and after the end of the study treatment (f/u). Measurable and evaluable tumor responses were assessed as defined by the WHO criteria. Duration of SD, for example, was defined as the time from study entry to the first radiological assessment meeting the criteria for SD. PFS time was defined as the time from study entry to first date of documented tumor progression or death. PFS was censored at the date of the last post-therapy follow-up visit for patients who were still alive and who had not progressed. Survival was defined as the time from study entry to time of death due to any cause. Survival time was censored at the time of the last post-therapy follow-up visit for patients who were still alive.
All patients who received at least one dose of bevacizumab were evaluated for safety and toxicity. Assessment of toxicity was conducted using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) investigator guide (Version 3.0).
Statistical considerations
The primary objective was the safety and toxicity profile of bevacizumab given with ICE. Secondary objectives were response rate and to determine PFS and OS using KaplanMeier estimators.
Results
Patient characteristics and disposition
Between June 2004 and May 2006, a total of 16 patients with refractory sarcoma (13 patients) and GCC (3 patients) were treated within this study. Patient characteristics are listed in Table 1 .
Safety and toxicity
All patients received a PBSC graft and experienced hematologic toxicity accordingly as indicated in Table 2 . In 5 cycles (9.8% of cycles), febrile neutropenia occurred with no septic deaths. No grade 2-4 cardiotoxicity was observed. Peripheral neuropathy grade 3 was seen in 4 cycles (2 patients), whereas grade 2 peripheral neuropathy was preexisting.
Ifosfamide encephalopathy was observed in 17 cycles of chemotherapy (31%). The three patients with grade 3 encephalopathy (one patient with cerebral metastasis) showed symptoms of drowsiness and confusion, which were completely reversible after 36 h. Cranial CT scan excluded bleeding or other unexpected findings.
In 3 of the 10 patients staying on study for 43 cycles required protocol-mandated ifosfamide, etoposide and carboplatin dose reductions by 25% due to impaired glomerular filtration rate. Dose reduction of bevacizumab was not required. Toxicities typically ascribed to bevacizumab observed infrequently. Nine patients reported selflimited epistaxis, with no case of grade 3-4 bleeding. There was one newly diagnosed deep venous thrombosis grade 3. Table 3 summarizes patient characteristics including best response to previous chemotherapy as well as response, PFS and survival of patients to the investigational treatment.
Efficacy parameters
Sarcoma patients. Four of the 13 sarcoma patients (30.8%) had a PR, 5 patients (38.5%) SD and 4 patients (30.8%) progressed. The overall response rate and the disease control rate was 30.8% (4 patients) and 69.2% (9 patients), respectively. From seven sarcoma patients who showed PD as 'best response' with the previous chemotherapy, two of these patients showed a PR and one patient SD with HD-ICE þ bevacizumab, with one patient still alive in October 2009 (62 months þ ). After the end of the study treatment, one patient received radiation therapy and one patient underwent surgery.
GCC patients. There was one nearly complete response (nCR, marker response 499%, radiological partial response near to complete response) reported in a patient with GCC who had PD as 'best response' to all three previous chemotherapies. The individuals' time to progression and survival was 5 and 9 months, respectively. The other two patients had a PR. After the end of the study treatment, one patient received radiation therapy and also underwent surgery.
PFS/OS in sarcoma patients. In the 13 sarcoma patients, median PFS was 4.0 months (Figure 1 , 95% confidence interval (CI): 1.2-6.8). The median OS for the patients with sarcoma was 13 months (95% CI: 3.6-24.4), with 2 patients still alive as October 2009 (follow-up 7.5-62 months).
Discussion
The primary aim of this study was to test the feasibility of the addition of bevacizumab to HD-ICE. Because of the small sample size and heterogeneity of the patient population also in terms of different histological subtypes, the study has to be interpreted with caution.
The hematologic toxicity of bevacizumab þ ICE was found to be comparable to that of similar regimens using PBSC rescue, in terms of duration of aplasia and number of transfusions. 4, 14 Febrile neutropenia was a manageable toxicity and seemed to be lower, as reported in the literature, with similar regimens used.
14 The major problem with this regimen was encephalopathy that occurred in 31% (all grades) of chemotherapy cycles. When compared with the literature, the incidence of encephalopathy in patients treated with ifosfamide is estimated to be between 10 and 30%. 15, 16 Lower albumin levels as a risk factor for developing encephalopathy were not found, in comparison to the patients with no encephalopathy, in our study. 17 Although not very likely, a leukencephalopathy syndrome in association of bevacizumab has to be discussed as reported by Glusker et al. 18 As we only performed a cranial CT scan in patients with grade 3 encephalopathy, which is not the appropriate method for diagnosing a leukencephalopathy, this remains a matter of speculation. 19 Of great importance is the observation in other studies that the combination of doxorubicin and bevacizumab resulted in unacceptably high levels of cardiomyopathy.
11
Although doxorubicin was not a component of our regimen, all 13 sarcoma patients were pretreated with this drug. In one trial, a 35% rate of grade 2 or greater cardiotoxicity with the combination of bevacizumab and doxorubicin was reported. 11 In our series, no severe cardiotoxicity was seen. An explanation could be the relatively young age (median 38 years) in our study in comparison to the study by D'Adamo with a median age of 54 years and no simultaneous use of doxorubicin and bevacizumab. It is important to note that the risk of central nervous system (CNS) hemorrhage in patients with CNS metastasis receiving bevacizumab plus HD chemotherapy could be increased due to the relatively long phase of thrombocytopenia. 19 None of our three patients with cerebral metastases experienced CNS hemorrhage. This is in accordance with a case report in a patient with brain metastases from a sarcoma and studies in patients with glioblastoma receiving bevacizumab who also experienced no early CNS hemorrhage. 20, 21 Individual safety data from several randomized colorectal cancer trials suggested that adding bevacizumab to the chemotherapy regimen might increase the risk of arterial thromboembolism in high-risk patients (age 465 years, prior arterial thromboembolism). 7 No arterial thromboembolism occurred in our study with no patients over 65 years with a history of arterial thromboembolism. Certainly no valid conclusion can be made due to the small sample size in our study. We hypothesized that the marginal benefit of HDCT might be improved by the addition of bevacizumab in this heavily pretreated group of patients in a situation where no further treatment option were available. This assumption was underlined by the observation of a potential reversal of chemotherapy resistance by the addition of bevacizumab in one case from our institution in a patient with highly refractory GCC. 22 The observed response rate in our study in patients with sarcoma was 30.8%. These results are very difficult to compare with other results obtained with HDCT because Table 3 Description of all patients including response to previous treatment, response, PFS to HD-ICE+ bevacizumab mostly patients with chemosensitive, non-refractory sarcomas were included in these trials. 4, 23 In the study by Kasper et al. 4 HD-ICE and HD melphalan were used. In this trial, 44% of the patients included were chemotherapy naive. As no response rates were specified, the median PFS and OS were 12 and 16.5 months, respectively, which compares with 4 months for PFS and 13 months for OS in patients with sarcoma in our study. Furthermore, in the study by Schlemmer et al. 23 using HD-ICE in 55 chemotherapy naive sarcoma patients, the response rate was 38%. It could be speculated that due to the addition of bevacizumab in our study, tumor growth could not be stopped but was at least slowed.
Considering the seven patients with sarcoma who had PD as best response with the last chemotherapy, 2 (28.6%) had a PR with our study regimen. This might indicate potential reversal of chemotherapy resistance by the addition of bevacizumab to HD-ICE. Until now, this potential ability to reverse chemoresistance has been described for EGFR-targeted agents but not for VEGFtargeted agents. 24 However, this has to be interpreted with great cautious due to the very small sample size and heterogeneity of the patient population in our study.
Regarding patients with GCC, the role of HDCT in patients truly refractory to standard dose platinum-based chemotherapy is also still unclear. VEGF is overexpressed and represents an independent risk factor in GCC. 12 Although the PFS was rather short-lived in two of the three patients with GCC, the observed response to thirdand fifth-line therapy itself was unexpected. Thus, it is tempting to speculate that bevacizumab might potentiate the activity of HDCT in GCC.
Future directions
Recently, studies on the angiogenesis inhibitors sorafenib, pazopanib and ABT-510 have shown interesting activity in terms of PFR in the treatment of certain subtypes soft tissue sarcomas. [25] [26] [27] Because of the paucity of treatment results with cytotoxic agents for soft tissue sarcomas, it is important to pursue antiangiogenics in combination with cytotoxic agents in further studies. 28 Furthermore, recent data also suggest a potential role for multitarget tyrosine kinase receptor inhibitors with antiangiogenic activities such as sunitinib in germ cell tumors even in cisplatin-refractory patients. 29 In conclusion, to our knowledge this is the first report of the addition of bevacizumab to high-dose chemotherapy (HD-ICE). The toxicities were manageable with no early deaths. The incidence of ifosfamide encephalopathy was the only toxicity, which tended to be higher than in previously reported studies using high-dose ifosfamide combinations.
The addition of bevacizumab potentially increases the efficacy of HDCT. The efficacy results in these heavily pretreated patients are promising, mainly in patients previously refractory to chemotherapy. However, it has to be emphasized that no final conclusions can be drawn from the observations until a randomized trial has been performed. Future designs formally investigating the role of bevacizumab in a randomized phase II study in the firstline (GCC) and salvage treatment (GCC and sarcoma) would be of major interest in this setting.
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